Tags : KEYNOTE-890

$OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer$

Pharma

OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890

Tuba Khan May 23, 2019

Shots: The P-II KEYNOTE-890 study results involve assessing of Keytruda (200mg, IV) + TAVO (tavokinogene telseplasmid) in 25 patients with heavily pretreated, CT/radiotherapy refractory mTNBC who failed an average of […]readmore

Tags : KEYNOTE-890

OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : KEYNOTE-890

﻿OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890